Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART).
Paterson DL, Rossi F, Baquero F, Hsueh PR, Woods GL, Satishchandran V, Snyder TA, Harvey CM, Teppler H, Dinubile MJ, Chow JW. Paterson DL, et al. Among authors: harvey cm. J Antimicrob Chemother. 2005 Jun;55(6):965-73. doi: 10.1093/jac/dki117. Epub 2005 Apr 22. J Antimicrob Chemother. 2005. PMID: 15849262
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.
Hirsch MS, Steigbigel RT, Staszewski S, McMahon D, Fischl MA, Hirschel B, Squires K, DiNubile MJ, Harvey CM, Chen J, Leavitt RY; Protocol 039 Study Group. Hirsch MS, et al. Among authors: harvey cm. Clin Infect Dis. 2003 Oct 15;37(8):1119-24. doi: 10.1086/378063. Epub 2003 Sep 18. Clin Infect Dis. 2003. PMID: 14523778 Clinical Trial.
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD; Protocol 005 Team. Grinsztejn B, et al. Among authors: harvey cm. Lancet. 2007 Apr 14;369(9569):1261-1269. doi: 10.1016/S0140-6736(07)60597-2. Lancet. 2007. PMID: 17434401 Clinical Trial.
Effects of omeprazole on plasma levels of raltegravir.
Iwamoto M, Wenning LA, Nguyen BY, Teppler H, Moreau AR, Rhodes RR, Hanley WD, Jin B, Harvey CM, Breidinger SA, Azrolan N, Farmer HF Jr, Isaacs RD, Chodakewitz JA, Stone JA, Wagner JA. Iwamoto M, et al. Among authors: harvey cm. Clin Infect Dis. 2009 Feb 15;48(4):489-92. doi: 10.1086/596503. Clin Infect Dis. 2009. PMID: 19143531
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arastéh K, Hoffmann C, Raffi F, Osiyemi O, Dretler R, Harvey C, Xu X, Plettenberg A, Smith DE, Portilla J, Rugina S, Kumar S, Frobose C, Wan H, Rodgers A, Hwang C, Teppler H. Gatell JM, et al. Antivir Ther. 2019;24(6):425-435. doi: 10.3851/IMP3323. Antivir Ther. 2019. PMID: 31355775 Clinical Trial.
Rapid Fabrication of Silica Microlens Arrays via Glass 3D Printing.
Liu C, Oriekhov T, Lee C, Harvey CM, Fokine M. Liu C, et al. Among authors: harvey cm. 3D Print Addit Manuf. 2024 Apr 1;11(2):460-466. doi: 10.1089/3dp.2022.0112. Epub 2024 Apr 16. 3D Print Addit Manuf. 2024. PMID: 38689924 Free PMC article.
61 results